Skip to content

To study if a smaller dose of propofol given prior to the actual dose will be able to reduce its total dose required.

To study the effect of Priming principle on the induction dose requirement of propofol

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025742
Enrollment
100
Registered
2020-06-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K35-K38- Diseases of appendix Health Condition 2: H65-H75- Diseases of middle ear and mastoid Health Condition 3: K80-K87- Disorders of gallbladder, biliary tract and pancreas Health Condition 4: K40-K46- Hernia Health Condition 5: C73-C75- Malignant neoplasms of thyroid and other endocrine glands

Interventions

Intervention1: DOSAGE ADJUSTMENT OF DRUG: in our study,we will be applying â??Priming principleâ??
a subanaesthetic dose administration of propofol, with the aim of reducing the induction dose requirement and hence, better haemodynamic stability following induction. Intervention2: PRIMING DOSE OF P
30% OF THE CALCULATED DOSE IS TAKEN AS THE PRIMING DOSE IN OUR STUDY. THEN THE REMAINING DOSE WILL BE GIVEN AFTER TWO MINUTES BASED ON THE LOSS OF VERBAL RESPONSE OF THE PATIENT. total calculated dos

Sponsors

REEHANA JABARULLA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA 1 and 2

Exclusion criteria

Exclusion criteria: H/O allergy to egg, opioids Alcoholics H/O intake of CNS depressants ASA 3 and 4 Haemodynamic instability BMI > 35 Anticipated difficult intubation Pregnancy and lactating mothers

Design outcomes

Primary

MeasureTime frame
To Study the Effect of Priming Principle on the Induction dose requirement of Propofol.Timepoint: 1 year

Secondary

MeasureTime frame
To Compare the Hemodynamics between the group in which Priming Principle was applied and the group in which No priming was applied. Timepoint: 1 year

Countries

India

Contacts

Public ContactR KAVITHA

PSGIMSR

jojopritam@gmail.com9840950928

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026